leadf
logo-loader
viewMedlab Clinical Ltd

Medlab's Hall: "Time to offer something new" to challenge reliance on opioids

Medlab

Medlab Clinical Ltd's (ASX:MDC) Sean Hall tells Proactive that the company is building a cannabis-based drug that is the size of a nanoparticle.

Hall adds that the company is currently intent on marketing the product in around 18 countries, including the EU, the US, Canada, and Australia.

Hall also says that the firm is currently talking to several pharmaceutical firms, two of which are of "significant note".

Quick facts: Medlab Clinical Ltd

Price: 0.19 AUD

ASX:MDC
Market: ASX
Market Cap: $53.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read